» Articles » PMID: 35014679

Survival‑related DLEU1 is Associated with HPV Infection Status and Serves As a Biomarker in HPV‑infected Cervical Cancer

Overview
Journal Mol Med Rep
Specialty Molecular Biology
Date 2022 Jan 11
PMID 35014679
Authors
Affiliations
Soon will be listed here.
Abstract

Human papillomavirus (HPV) is the most common risk factor for the occurrence of cervical cancer (CC). In recent years, the important roles of long non‑coding RNAs (lncRNAs) in CC have emerged, but studies on the relationship between lncRNAs and HPV‑positive (HPV+) CC remain scarce. The present study aimed to investigate whether lncRNA deleted in lymphocytic leukemia 1 (DLEU1) is associated with HPV infection and explore the clinical significance of DLEU1 in HPV+ patients with CC. DLEU1 expression was detected by reverse transcription‑quantitative PCR. The ability of DLEU1 to screen patients with CC from controls and differentiate individuals with different HPV infection status was evaluated by receiver operating characteristic analysis. The association of DLEU1 with the survival prognosis of patients with CC was assessed by Kaplan‑Meier survival analysis and Cox regression analysis. The RNA Interactome Database was used to predict molecules interacting with DLEU1. The results indicated that DLEU1 expression was significantly upregulated in CC tissues and cell lines, particularly in those that were HPV+. In addition, DLEU1 had a high diagnostic value in discriminating patients with CC and differentiating between HPV+ and HPV‑ patients with CC, and had a certain ability to screen HPV+ controls. DLEU1 was correlated with HPV infection in CC patients. Furthermore, DLEU1 was indicated to be associated with survival prognosis in both total patients with CC and HPV+ patients with CC, and independently predict the prognosis of patients with CC. Most of the molecules interacting with DLEU1 were microRNAs. In conclusion, abnormal DLEU1 expression is associated with HPV infection and may serve as a diagnostic and prognostic biomarker for HPV+ patients with CC.

Citing Articles

The expression and clinical significance of serum exosomal-long non-coding RNA DLEU1 in patients with cervical cancer.

Chen Y, Cui F, Wu X, Zhao W, Xia Q Ann Med. 2024; 57(1):2442537.

PMID: 39687982 PMC: 11654034. DOI: 10.1080/07853890.2024.2442537.


Effects of Sintilimab Plus Radiotherapy on Levels of Spondin-2 and Glucose Transporter-1 in Patients with Cervical Cancer.

Yang H, Chen Z, Lou H, Ying W, Chai Z Int J Gen Med. 2024; 17:2931-2937.

PMID: 38978713 PMC: 11228073. DOI: 10.2147/IJGM.S461606.


Value of high‑risk human papillomavirus detection combined with colposcopy in the diagnosis of cervical cancer and precancerous lesions.

Wang P, Gao D, Yu X, Zhu G Oncol Lett. 2024; 27(4):185.

PMID: 38476208 PMC: 10928995. DOI: 10.3892/ol.2024.14318.


RIPOR2 Expression Decreased by HPV-16 E6 and E7 Oncoproteins: An Opportunity in the Search for Prognostic Biomarkers in Cervical Cancer.

Olmedo-Nieva L, Munoz-Bello J, Martinez-Ramirez I, Martinez-Gutierrez A, Ortiz-Pedraza Y, Gonzalez-Espinosa C Cells. 2022; 11(23).

PMID: 36497200 PMC: 9740487. DOI: 10.3390/cells11233942.

References
1.
Zamani S, Sohrabi A, Hosseini S, Rahnamaye-Farzami M, Akbari A . Deregulation of miR-21 and miR-29a in Cervical Cancer Related to HPV Infection. Microrna. 2018; 8(2):110-115. DOI: 10.2174/2211536607666181017124349. View

2.
Jiang S, Qi Y, He R, Huang Y, Liu Z, Ma Y . Human cytomegalovirus microRNA miR-US25-1-5p inhibits viral replication by targeting multiple cellular genes during infection. Gene. 2015; 570(1):108-14. DOI: 10.1016/j.gene.2015.06.009. View

3.
Zhang X, Wang Y, Zhao A, Kong F, Jiang L, Wang J . Long Non-Coding RNA LINC00511 Accelerates Proliferation and Invasion in Cervical Cancer Through Targeting miR-324-5p/DRAM1 Axis. Onco Targets Ther. 2020; 13:10245-10256. PMC: 7567551. DOI: 10.2147/OTT.S255067. View

4.
Razavi Z, Tajiknia V, Majidi S, Ghandali M, Mirzaei H, Rahimian N . Gynecologic cancers and non-coding RNAs: Epigenetic regulators with emerging roles. Crit Rev Oncol Hematol. 2020; 157:103192. DOI: 10.1016/j.critrevonc.2020.103192. View

5.
Li J, Chu Z, Han H, Zhang Y, Tian F, Zhang J . Suppression of miR-93-5p inhibits high-risk HPV-positive cervical cancer progression via targeting of BTG3. Hum Cell. 2019; 32(2):160-171. DOI: 10.1007/s13577-018-00225-1. View